SEAAIS 2022 77th Annual Meeting

September 15, 2022 to September 18, 2022

The SEAAIS 2022 meeting is focused on the field of Allergy Asthma and Immunology.  It is directed to physicians, physician assistants, nurse practitioners and administrators.  The purpose is to engage the audience through oral didactic presentations followed by group discussions.  Each presentation is reflective of a need or interest of in-depth conversation or study requested by the membership and/or board.  Case presentations are often utilized to solidify the objectives covered in each presentation.

Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of American College of Allergy, Asthma & Immunolgy and Southeastern Allergy, Asthma, & Immunology Society. The American College of Allergy, Asthma & Immunolgy is accredited by the ACCME to provide continuing medical education for physicians.”

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this live activity for a maximum of 13 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Target Audience

Practicing allergists
Allied health professionals

Learning Objectives

Upon completion of this activity the participant should be able to:

1.  Understand the upper and lower airway connection and understand the evidence for use of biologics in asthma.
2.  Review the impact of covid on asthma and review the treatment of upper and lower airways in patients with covid.
3.  Analyze and evaluate the different treatments for patients with CRSwNP and summarize the new and emerging targeted biologics for CRSwNP.
4.  Learn the scope and cause of physician burnout now with covid and be knowledgeable on organization and wellness initiatives for allergists.
5.  Discuss and learn the proper diagnostic evaluation of chronic cough an understand the term refractory chronic cough and current treatment options.
6.  Examine the current literature dealing with vaccine hesitancy and Covid-19 vaccines and provide a classification of adverse reactions related to Covid-19 vaccines.
7.  Define the general clinical characteristics of long Covid and provide a proposed mechanistic model of pathogenesis of the syndrome.
8.  Understand and discuss payment challenges for allergy codes by MCOs and understand in-office implementation of USP 797.
9.  Discuss limitations of routine diagnostic testing in chronic urticaria and discuss management options for refractory chronic urticaria.
10.  Analyze and evaluate the different treatments for patients with atopic dermatitis and summarize the new and emerging targeted biologics for atopic dermatitis. 
11.  Define different types of mast cell activation disorders and discuss workup and diagnostic criteria for each.
12. Evaluate different diagnostic modalities for food allergy and recognize novel therapeutic strategies for IgE-mediated food allergy.
13.  Recognize updates in recent guidelines for anaphylaxis and develop a diagnostic algorithm for patients presenting with idiopathic anaphylaxis.
14.  To review the mechanisms of selling in HAE and provide an update on treatment options.
15.  Understand the landscape of medical practice, discuss how to value a practice and explain options for practice ownership/partnership.
16.  Gain an understanding of the laboratory assessment of CVID and discuss the non-infectious complications of CVID.
17.  Define low T2 Asthma and review the pathophysiology underlying different types of low T2 Asthma.

Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. The ACCME defines an “ineligible company” as companies whose primary business is producing, marketing, re-selling, or distributing health care goods or services, used by or on patients. Examples of such organizations include:

Ambulatory procedure centers

  • Blood banks
  • Diagnostic labs that do not sell proprietary products
  • Electronic health records companies
  • Government or military agencies
  • Group medical practices
  • Health law firms
  • Health profession membership organizations
  • Hospitals or healthcare delivery systems
  • Infusion centers
  • Insurance or managed care companies
  • Nursing homes
  • Pharmacies that do not manufacture proprietary compounds
  • Publishing or education companies
  • Rehabilitation centers
  • Schools of medicine or health science universities
  • Software or game developers

 

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All identified conflicts of interest have been mitigated

Course summary
Available credit: 
  • 13.00 AMA PRA Category 1 Credit™
  • 13.00 Attendance
Course opens: 
09/15/2022
Course expires: 
12/31/2023
Event starts: 
09/15/2022 - 8:00am CDT
Event ends: 
09/18/2022 - 11:15am CDT
Rating: 
0

Disclosure Policy and Disclosures
As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewer, and other individuals in a position to control or influence the content of an activity must disclose ALL financial relationships with any ineligible company. The ACCME defines an “ineligible company” (formerly commercial interest) as a company whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. (Examples of ineligible companies include: Advertising, marketing, or communication firms whose clients are ineligible companies; bio-medical startups that have begun a governmental regulatory approval process; compounding pharmacies that manufacture proprietary compounds; device manufacturers or distributors; diagnostic labs that sell proprietary products; growers, distributors, manufacturers or sellers of medical foods and dietary supplements; manufacturers of health-related wearable products; pharmaceutical companies or distributors; pharmacy benefit managers; reagent manufacturers or sellers). For more information, visit www.accme.org.

 Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI.

 All identified conflicts of interest have been mitigated. 

Michael Blaiss, MD, Speaker: Consultant:  Sanofi, Regeneron, AZ, Amgen, Merck, Pfizer, Perrigo, Covis, ALK, TerSera, Lanier Biotherapeutics

Peter Dicpinigaitis, MD, Speaker: Consultant:  Bayer, Bellus, Chiesi, Merck, Regeneron, Shionogi; 

Weily Soong, MD, Speaker: Research Investigator: Allakos, AstraZeneca, Lilly, Novartis, Genentech, Regeneron, and Sanofi; Consultant or Speaker:  AstraZeneca, GSK, Genentech, Novartis, Regeneron, and Sanofi.

Anju Peters, MD, Speaker: Research: Optinose, Sanofi Regeneron; Consulting:  AstraZeneca, GSK, Optinose, Sanofi Regeneron

Matthew Giannetti, MD, Speaker: Research:  Blueprint Medicines, Cogent Biosciences; Consulting:  Cogent Biosciences

Jay Lieberman, MD, Speaker: Research/Advisor:  DBV Technologies, Aimmune Therapeutics, Regneron, Alk-Abello, Novartis

Marc Riedl, MD, Speaker: Research:  Biocryst, Biomarin, CSL Behring, Ionis, Kalvista, Pharvaris, Takeda; Speaker:  CSL Behring, Pharming, Takeda; Consulting:  Astria, Biocryst, Biomarin, CSL Behring, Cycle Pharma, Fresenius-Kabi, Ipsen, Kalvista, Ono Pharma, Pfizer, Pharming, Pharvaris, RegenexBio, Sanofi-Regeneron, Shire/Takeda 

Tara Carr, MD, Speaker: Consulting/Advisor:  AstraZeneca, Genentech, Roche; Royalties: Editorial compensation and royalties from UpToDate

The following have no relevant financial relationships to disclose:
Joseph Bellanti, MD

James Sublett, MD

Stanley Fineman, MD

 

 

Available Credit

  • 13.00 AMA PRA Category 1 Credit™
  • 13.00 Attendance
Please login or create an account to take this course.